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OBJECTIVE—To determine the relative risk associated with
DPA1 and DPB1 alleles and haplotypes in type 1 diabetes.
RESEARCH DESIGN AND METHODS—The frequency of
DPA1 and DPB1 alleles and haplotypes in type 1 diabetic patients
was compared to the family based control frequency in 1,771
families directly and conditional on HLA (B)-DRB1-DQA1-DQB1
linkage disequilibrium. A relative predispositional analysis (RPA)
was performed in the presence or absence of the primary HLA
DR-DQ associations and the contribution of DP haplotype to
individual DR-DQ haplotype risks examined.
RESULTS—Eight DPA1 and thirty-eight DPB1 alleles forming
seventy-four DPA1-DPB1 haplotypes were observed; nineteen
DPB1 alleles were associated with multiple DPA1 alleles. Follow-
ing both analyses, type 1 diabetes susceptibility was signiﬁcantly
associated with DPB1*0301 (DPA1*0103-DPB1*0301) and protec-
tion with DPB1*0402 (DPA1*0103-DPB1*0402) and DPA1*0103-
DPB1*0101 but not DPA1*0201-DPB1*0101. In addition, DPB1*
0202 (DPA1*0103-DPB1*0202) and DPB1*0201 (DPA1*0103-
DPB1*0201) were signiﬁcantly associated with susceptibility in
the presence of the high risk and protective DR-DQ haplotypes.
Three associations (DPB1*0301, *0402, and *0202) remained
statistically signiﬁcant when only the extended HLA-A1-B8-DR3
haplotype was considered, suggesting that DPB1 alone may
delineate the risk associated with this otherwise conserved
haplotype.
CONCLUSIONS—HLA DP allelic and haplotypic diversity con-
tributes signiﬁcantly to the risk for type 1 diabetes; DPB1*0301
(DPA1*0103-DPB1*0301) is associated with susceptibility and
DPB1*0402 (DPA1*0103-DPB1*0402) and DPA1*0103-DPB1*0101
with protection. Additional evidence is presented for the suscep-
tibility association of DPB1*0202 (DPA1*0103-DPB1*0202) and
for a contributory role of individual amino acids and DPA1 or a
gene in linkage disequilibrium in DR3-DPB1*0101 positive
haplotypes. Diabetes 59:2055–2062, 2010
I
nsulin-dependent autoimmune or type 1 diabetes is a
common autoimmune disorder of unknown etiology
which results in the destruction of the insulin-
secreting pancreatic -cells. The concordance rate
in monozygotic twins is estimated to be 30 to 50% with an
average risk to sibs of 6% (1) and an overall genetic risk
ratio (-s) of about 15 (2). The increasing incidence of type
1 diabetes in a genetically homogeneous population, how-
ever, clearly indicates that environmental factors also play
a key role (3,4).
Multiple association studies and genome linkage and
association scans have conﬁrmed that the greatest genetic
risk is associated with variation within the HLA region
located on chromosome six with evidence for modest
associations at other regions in addition to HLA (5,6). In
particular allelic, haplotypic or genotypic differences at
the HLA class II DRB1, DQA1 or DQB1 loci have been
shown in many studies, including a subset of this dataset
(7), to have the greatest association.
The most plausible mechanism explaining the associa-
tion with genes of the HLA class II region is their role in
presentation of peptides derived from exogenous protein
to CD4 T-helper cells which, in the case of type 1
diabetes, may result in an inappropriate T cell immune
response against self-antigens on the pancreatic -cells.
Allelic differences at the DRB1, DQA1 and DQB1 loci have
been shown to inﬂuence the peptide binding and T cell
stimulatory capacities of the individual HLA molecules (8),
suggesting that such differences contribute to the associ-
ation of individual or groups of alleles with autoimmune
diseases. Genetic polymorphisms at other loci, both within
and outside the HLA region may, in addition, contribute to
and inﬂuence the magnitude of the immune response.
The HLA DPA1 and DPB1 genes are the third set of
classical HLA class II loci which code for the DP antigen
and have been associated with a lower immunostimulatory
capacity and level of expression (9,10) although differ-
ences at individual DPB amino acids have been associated
with an increased proliferative response in the mixed
lymphocyte reaction (11,12). Similarly, a single DPB amino
acid, glutamic acid at position 69, has been shown to
contribute to graft versus host disease in otherwise HLA
identical sibling bone marrow transplantation (13) and
susceptibility to Beryllium disease (14).
Association studies of HLA-DPB1 and type 1 diabetes
have shown multiple associations with conﬂicting re-
From the
1Victorian Transplantation & Immunogenetics Service, Australian
Red Cross Blood Service, Melbourne, Australia;
2Department of Twin
Research, King’s College London, London, UK;
3Clinical Chemistry, Univer-
sity Hospital, Malmo ¨, Sweden;
4Children’s Hospital Oakland Research
Institute, Oakland, California;
5Roche Molecular Systems, Alameda, Califor-
nia; and
6Public Health Sciences, Bioinformatics & Genetics Center for
Public Health Genomics, University of Virginia, Charlottesville, Virginia.
Corresponding author: Michael D. Varney, MVarney@arcbs.redcross.org.au.
Received 6 May 2009 and accepted 20 April 2010. Published ahead of print at
http://diabetes.diabetesjournals.org on 27 April 2010. DOI: 10.2337/db09-0680.
© 2010 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
ORIGINAL ARTICLE
diabetes.diabetesjournals.org DIABETES, VOL. 59, AUGUST 2010 2055sults. The following have been reported as susceptibility
alleles in populations of different ethnic backgrounds:
DPB1*0201, *0202, *0301, *0401, *0402, *1701 and the
following as protective alleles; DPB1*0101, *0202, *0401,
*0402, *1701 (15–23). Other studies have reported weak or
no association with HLA DPB1 alleles (24,25). The con-
ﬂicting nature of these association studies may be a
reﬂection of population speciﬁc differences, inconsistent
typing approaches, differences in study design or inade-
quately powered studies.
The HLA DPA1 and DPB1 loci are highly polymorphic
with 28 DPA1 and 136 DPB1 alleles deﬁned as of October,
2009 (http://www.ebi.ac.uk/imgt/hla/). Association analy-
ses in the HLA region are complicated by the occurrence
of extensive linkage disequilibrium between loci such that
the classical HLA loci, A, B, C, DR, DQ and DP, as well as
other genes in this region, are often inherited as a “block”.
The DR/DQ recombination frequency per meiosis between
DR-DQ and DP has been estimated to range between 1–3%
(13,26). Estimates of the relative contribution of HLA DP
to susceptibility or protection against type 1 diabetes must
therefore consider the potential inﬂuence of co-inherited
loci, some of which are strongly associated with type 1
diabetes.
The Type 1 Diabetes Genetic Consortium (T1DGC) is a
large worldwide collaborative study of type 1 diabetes
families that have been collected in a highly standardized
fashion from various populations (27). High resolution
HLA typing has been performed at eight loci at four
genotyping centers using standardized typing protocols
and reagents (28). The large sample size and addition of
DPA1 typing permits, for the ﬁrst time, an association
analysis of the DPA1 locus in addition to DPB1 and
DPA1-DPB1 haplotypes, which encode the antigen pre-
senting alpha and beta chain heterodimer with type 1
diabetes.
RESEARCH DESIGN AND METHODS
The dataset used comprised 1,149 new Caucasian type 1 diabetes multiplex
families combined with a number of existing type 1 diabetes DNA collections
that are largely Caucasian, some of which have previously been HLA typed
and analyzed (20,23), including the Danish (n  95), Human Biological Data
Interchange (HBDI) repository (Philadelphia, PA; n  418), Sardinian (n 
52), and Joslin Diabetes Collections (n  57). Where the proband was not
indicated an affected sib was chosen at random.
Genotyping. The methods of HLA genotyping have previously been described
(7). Brieﬂy, four digit HLA typing was reported using oligonucleotide probes
that were immobilized to a nylon membrane and hybridized with biotin-
labeled locus speciﬁc PCR products. Genotyping was performed using the
Stripscan and Score proprietary software prior to upload to the central
coordinating committee. Regular quality assurance typing performed on blind
samples and between laboratories indicate typing agreement to be greater
than 98% for DPA1 and DPB1 (28).
Statistical analysis. Control haplotypes (n  2,759) were determined based
on the affected family-based control (AFBAC) method (29). The statistical
signiﬁcance of differences in allele frequencies between type 1 diabetes
probands and AFBACs was assessed using a Pearson’s 
2 test. P values were
adjusted for multiple alleles or haplotypes by applying the Bonferroni correc-
tion of multiplying the nominal P value by the number of alleles or haplotypes
compared (Padj). Only alleles or haplotypes for which f  5% in either proband
or AFBAC or where the nominal P  0.05 and f  1% were compared. We note
that the Bonferroni correction is conservative for these data as the haplotypes
are not independent.
Because only the proband from each family is used in the analysis and the
AFBAC method uses at most two haplotypes from each pedigree, this
approach does not introduce a bias due to the nonindependence between sibs.
Adjustment for linkage disequilibrium (LD) with DR-DQ (HLA-B)
haplotypes. The expected allele frequencies were computed, given LD and
relative haplotype penetrance. In this case the null hypothesis (H0) is that
DPA1, or DPB1 allele or DPA1-DPB1 haplotype frequencies will differ between
patients and controls due to (1) linkage disequilibrium between DP and
DRB1-DQB1 (and eventually also HLA-B) and (2) due to chance (sampling),
thus implying that DP is neutral relative to disease predisposition.
Under H0 the expected allele frequencies at DPB1 or DPA1 alleles or
DPA1-DPB1 haplotypes can be computed using the equation derived by
Thomson (30):
qexp DPj  pDPj 
i
K
Dij
qDR-DQ-(DP)i
pDR-DQ-(DP)i
where Dij denotes pairwise linkage disequilibrium between the ith DR-DQ
(HLA-B) haplotype and the jth DPB1 or DPA1 allele or DPA1-DPB1 haplotype
in the control sample, q denotes the allele or haplotype frequency in probands,
p denotes frequency in AFBACs, and qexp denotes the expected frequency in
probands under the assumption of no involvement in disease. This method
relies on sampling estimates of pairwise linkage disequilibrium between DP
and DRB1-DQB1 and of the proband and control frequencies derived from the
samples under study. Thus, there will be a sampling error associated with the
computed value for expected DP allele or haplotype frequencies. The larger
the control sample the smaller this error would be. This has been taken into
account in the statistical tests carried out as previously described (31). Given
the large number of DR-DQ-B haplotypes and the error that very rare
haplotypes could introduce, only haplotypes at the susceptibility loci with an
average frequency of 0.5% or higher in combined cases and controls were
used. Moreover, only DP-DR-DQ (B) haplotypes where the expected fre-
quency in controls in the absence of LD would be 0.05% were included in the
analysis. Of the 75 observed DPA1-DPB1 haplotypes, a statistical test for
association with type 1 diabetes conditional on DR-DQ or DR-DQ-HLA-B was
carried out only on 22 haplotypes which had an expected frequency in type 1
diabetes of 0.5%.
In addition, the contribution of DP was considered on individual DRB1-
DQA1-DQB1 and extended HLA haplotypes by a direct comparison between
the allele and haplotype distribution between proband and AFBAC for
individual haplotypes.
RESULTS
Frequency distribution of DPA1 and DPB1 alleles and
haplotypes. Eight DPA1 and thirty-eight DPB1 alleles
were observed which formed seventy-four different DPA1-
DPB1 haplotypes; nineteen DPB1 alleles were associated
with multiple DPA1 alleles. The most frequent DPB1 allele,
*0401, was observed in association with ﬁve different
DPA1 alleles. While the DPA1-DPB1 haplotypic diversity is
much greater than that previously observed, only fourteen
DPA1-DPB1 haplotypes were observed at a frequency
of greater than one percent in either the probands or
AFBACs. The inclusion of DPA1 in HLA-DP associations
with type 1 diabetes permits, for the ﬁrst time, an analysis
of the contribution of this locus and an analysis of
DPA1-DPB1 haplotypes.
A direct comparison of the DPA1, DPB1, and DPA1-
DPB1 frequency distribution, unadjusted for linkage dis-
equilibrium, reveals a signiﬁcant association with
susceptibility to type 1 diabetes with DPB1*0101, 0202,
0301 and the DPA1-DPB1 haplotypes; 0201-0101, 0103-
0202, 0103-0301. Protection against type 1 diabetes was
signiﬁcantly associated with DPA1*0202, DPB1*0402,
1001, 1101 and the DPA1-DPB1 haplotypes; 0103-0402,
0201-1101 (Table 1). DPB1*0101 was the only DPB1 allele
observed with multiple DPA1 alleles that each had a
frequency greater than 1% allowing analysis of the role of
DPA1 in type 1 diabetes risk.
Association analyses of HLA-DP with type 1 diabetes are
complicated by the presence of extensive linkage disequi-
librium between HLA loci that include the established
primary susceptibility and protective DRB1, DQA1, and
DQB1 loci. To address the issue of linkage disequilibrium,
association analyses were performed conditional on
DRB1-DQA1-DQB1 linkage disequilibrium (Table 2) and
HLA-B-DRB1-DQA1-DQB1 linkage disequilibrium (Fig. 1)
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ses which indicate an independent association of HLA-B
(32,33). In addition, a relative predispositional analysis
(RPA) (34) in which the primary susceptibility and protec-
tive DRB1-DQA1-DQB1 haplotypes are removed was per-
formed to detect secondary associations not detected in
the presence of the primary associations. Furthermore, an
association analysis was performed comparing the fre-
quency of DPA1-DPB1 haplotypes present on the more
frequent individual DRB1-DQA1-DQB1 haplotypes.
Conditional analysis
DPA1. Following the correction for multiple allele testing,
only DPA1*0201 (Padj  5  10
	4,O R 0.7) was signiﬁ-
cantly associated with protection to type 1 diabetes.
DPA1*0201 was also protective when in haplotypic asso-
ciation with four DPB1 alleles; 0101, 0401, 1001 and 1101.
TABLE 1
Proband and affected family-based control (AFBAC) HLA DPA1, DPB1 allele, and DPA1-DPB1 haplotype frequency distribution in
1,771 type 1 diabetes families
AFBAC (%)
(n  2,759)
Proband (%)
(n  3,542) Padj
Odds
Ratio 95% CI
AFBAC (%)
(n  2,759)
Proband (%)
(n  3,542) Padj
Odds
Ratio 95% CI
DPA1*
0103 82.4 83.6 1.1
0104 0.5 1.1 2.0 1.1–3.6
0201 13.7 13.5 1.0 0.8–1.2
0202 3.2 1.6 2E-4 0.5 0.4–0.7
DPB1* DPA1*-DPB1*
0101 5.6 7.4 0.05 1.4 1.1–1.7 0103-0101 1.3 0.6 0.5 0.3–0.8
0201-0101 3.4 6.4 2E-6 1.9 1.5–2.5
0202-0101 0.9 0.4 0.5 0.2–0.9
0201 13.5 15.2 1.1 1.0–1.4 0103-0201 12.6 14.9 1.2 1.0–1.4
0202 0.7 2.8 7E-9 4.4 2.6–7.3 0103-0202 0.5 2.8 5E-10 5.3 3.0–9.1
0301 10.4 15.9 5E-8 1.6 1.4–1.9 0103-0301 10.1 15.6 2E-8 1.7 1.4–2.0
0401 42.0 40.2 0.9 0103-0401 40.8 39.3 0.9
0402 11.5 5.3 9E-17 0.4 0.4–0.5 0103-0402 11.2 5.1 1E-16 0.4 0.3–0.5
1001 1.8 1.0 0.04 0.5 0.3–0.8 0103-0601 1.5 2.2 1.5 1.0–2.2
1101 2.1 0.9 9E-4 0.4 0.3–0.7 0201-1001 1.5 0.9 0.6 0.4–0.9
1401 1.3 0.8 0.6 0.4–1.0 0201-1101 1.7 0.8 0.02 0.5 0.3–0.8
1501 0.7 1.5 2.1 1.2–3.5 0104-1501 0.5 1.0 2.0 1.0–3.7
1701 1.7 1.0 0.6 0.4–0.9 0201-1701 1.6 1.0 0.6 0.4–1.0
Only alleles or haplotypes with a frequency 5% in an individual category or 1% where the nominal P value was 0.05 were compared. The
nominal P value was adjusted (Padj) for multiple alleles or haplotypes by applying the Bonferroni correction of multiplying the nominal P
value by the number of alleles or haplotypes compared.
TABLE 2
Expected and observed proband DPA1, DPB1, and DPA1-DPB1 frequencies conditioned on HLA DRB1-DQA1-DQB1 linkage
disequilibrium in 1,771 type 1 diabetes families
Proband
Fexp (%)
Proband
Fobs (%) Padj
Odds Ratio
(Fobs/Fexp) 95% CI
Proband
Fexp (%)
Proband
Fobs (%) Padj
Odds Ratio
(Fobs/Fexp) 95% CI
DPA1* DPA1-DPB1
0103 80.3 82.8 1.2
0104 0.5 1.0 2.0 1.1–3.7
0201 17.2 13.4 5E-4 0.7 0.6–0.9
0202 2.0 2.8 1.4 1.0–2.0
DPB1*
0101 11.4 8.0 2E-4 0.7 0.6–0.8 0103-0101 2.8 0.7 2E-10 0.2 0.1–0.4
0201-0101 7.5 6.3 0.8 0.7–1.0
0201 13.0 15.2 1.2 1.0–1.4 0103-0201 12.1 14.7 1.3 1.1–1.5
0202 1.4 2.8 2E-3 2.0 1.4–3.0 0103-0202 1.4 2.8 2E-3 2.1 1.4–3.0
0301 10.1 15.6 4E-8 1.6 1.4–2.0 0103-0301 10.0 15.3 5E-8 1.6 1.4–1.9
0401 40.8 39.9 1.0 0103-0401 38.9 38.7 1.0 0.9–1.1
0201-0401 1.2 0.7 0.6 0.3–1.0
0402 10.9 5.3 2E-14 0.5 0.4–0.6 0103-0402 10.7 5.1 7E-15 0.5 0.4–0.5
0501 1.1 1.7 1.6 1.0–2.5
0601 1.5 2.2 1.5 1.0–2.3 0103-0601 1.4 2.2 1.6 1.1–2.3
1001 1.7 1.0 0.6 0.4–0.9 0201-1001 1.7 0.9 0.05 0.5 0.3–0.8
1101 1.6 0.9 0.5 0.3–0.9 0201-1101 1.6 0.8 0.03 0.5 0.3–0.8
1501 0.5 1.5 2E-3 3.0 1.6–5.4 0104-1501 0.5 1.0 2 1.1–3.7
Only alleles or haplotypes with a frequency 5% in an individual category or 1% where the nominal P value was 0.05 were compared. The
nominal P value was adjusted (Padj) for multiple alleles or haplotypes by applying the Bonferroni correction of multiplying the nominal P
value by the number of alleles or haplotypes compared.
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to signiﬁcantly contribute to the risk associated with
DPB1*0101 (described below).
DPB1. DPB1*0301 was associated with susceptibility fol-
lowing the DRB1-DQA1-DQB1 conditional analysis (Padj 
4  10
	8,O R 1.6) and in haplotypic association with
DPA1*0103 (Padj  5  10
	8,O R 1.6). DPB1*0402 was
associated with protection following the DRB1-DQA1-
DQB1 conditional analysis (Padj  2  10
	14,O R 0.5)
and in haplotypic association with DPA1*0103 (Padj  7 
TABLE 3
Relative predispositional analysis; DPA1, DPB1 allele, and DPA1-DPB1 haplotype frequency distribution in 1,771 type 1 diabetes
families in the presence or absence of the high-risk and protective DRB1-DQA1-DQB1 haplotypes
Presence of high-risk and protective
DR-DQ haplotypes
Absence of high-risk and protective
DR-DQ haplotypes
% AFBACs
(n  1,102)
% Probands
(n  2,626) Padj
Odds
Ratio 95% CI
% AFBACs
(n  1,656)
% Probands
(n  916) Padj
Odds
Ratio 95% CI
DPA1*
0103 83.7 83.7 1.0 81.5 83.4 1.1 1.0–1.2
0104 0.7 2.2 0.002 3.3 1.6–7.0
0201 14.2 14.4 1.0 0.8–1.3 13.3 10.9 0.8 0.6–1.0
DPB1*
0101 9.5 9.3 1.0 0.8–1.3
0201 9.6 15.3 1E-04 1.7 1.3–2.2 16.1 15.0 0.9 0.7–1.2
0202 1.3 3.7 8E-04 2.9 1.7–5.2
0301 8.7 14.9 1E-05 1.8 1.4–2.4 11.5 18.6 3E-05 1.8 1.4–2.2
0401 50.5 40.6 2E-04 0.7 0.5–0.8
0402 6.4 4.8 0.7 0.5–1.0 14.9 6.8 7E-08 0.4 0.3–0.6
1501 0.8 2.8 3E-04 3.7 1.9–7.2
2301 1.3 0.2 5E-04 0.1 0.04–0.4
DPA1-DPB1
0103-0101 2.5 0.8 7E-04 0.3 0.2–0.6
0201-0101 7.0 8.2 1.2 0.9–1.6
0103-0201 9.3 14.9 1E-04 1.7 1.4–2.2 14.9 14.7 1.0 0.8–1.3
0103-0202 1.1 3.7 2E-04 3.4 1.9–6.3
0103-0301 8.4 14.6 1–05 1.9 1.5–2.4 11.2 18.6 7E-06 1.8 1.4–2.3
0103-0401 49.5 39.7 2E-04 0.7 0.5–0.8 35.1 38.1 1.1 1.0–1.4
0103-0402 6.4 4.6 0.7 0.5–1.0 14.4 6.4 6E-08 0.4 0.3–0.6
0103-2301 1.3 0.2 5E-05 0.1 0.04–0.4
0104-1501 0.3 0.2–0.6 0.6 2.2 2E-03 3.7 1.7–7.9
DPA1, DPB1, and DPA1-DPB1 alleles and haplotypes with a frequency 5% in an individual category or 1% where the nominal P value was
0.05 were compared in the presence or absence of the following high-risk and protective DRB1-DQA1-DQB1 haplotype: 0301-0501-0201,
0401-0301-0302, 0402-0301-0302, 0404-0301-0302, 0405-0301-0302, 0701-0201-0303, 1401-0101-0503 and 1501-0102-0602. The nominal P value
was adjusted (Padj) for multiple alleles or haplotypes by applying the Bonferroni correction of multiplying the nominal P value by the number
of comparisons.
TABLE 4
DPA1-DPB1 haplotype frequency odds ratios for individual DRB1-DQA1-DQB1 haplotypes
DRB1-DQA1-DQB1
Proband
(n)
AFBAC
(n)
DPA1-DPB1
0103-0101 0201-0101 0103-0201 0103-0202 0103-0301 0103-0402
OR Padj OR OR OR Padj OR P OR Padj
04XX-0301-0302 1,393 239 1.4 1.6 0.7
0401-0301-0302 909 114 0.2 0.04 1.6 2.0 0.7
0402-0301-0302 135 36 2.2 1.9 0.5
0404-0301-0302 223 90 1.2 1.6 0.9
0301-0501-0201 1,224 342 0.2 5.E-06 0.8 1.5 2.5 0.04 1.7 0.4 5.E–03
A1-B8-DR3 436 146 0.3 0.8 1.9 3.5 0.03 1.2 0.03 0.4 0.04
A30-B18-DR3 99 26 0.4 3.0 0.8 0.9
DR3 other 691 170 0.1 5.E-06 0.8 1.5 2.2 1.3 0.5
0101-0101-0501 195 236 0.8 2.2 0.3 1.E–03
1302-0103-0604 93 80 0.7 1.9 0.1 0.02
0701-0201-0201 94 270 1.0 1.1 0.3
1101-0501-0301 32 162 2.1 1.8 0.2
0401-0301-0301 63 111 2.2 0.4
The odds ratio (OR) was calculated for DPA–DPB1 haplotypes with a frequency 5% in an individual category or 1% where the nominal
P value was 0.05. The nominal P value was adjusted (Padj) for multiple alleles or haplotypes by applying the Bonferroni correction of
multiplying the nominal P value by the number of comparisons. DR3 (DRB1*0301-DQA1*0501-DQB1*0201) positive haplotypes were
subdivided into the presence or absence of the extended A*0101-B*0801-C*0701-DRB1*0301-DQA1*0501-DQB1*0201 and A*3002-B*1801-
C*0501-DRB1*0301-DQA1*0501-DQB1*0201 positive haplotypes.
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	15,R R 0.5). DPB1*0101 was associated with protec-
tion following the DRB1-DQA1-DQB1 conditional analysis
(Padj  2  10
	4,O R 0.7) and in haplotypic association
with DPA1*0103 (Padj  2  10
	10,O R 0.2). However,
no association was observed with the more common
DPA1*0201-DPB1*0101 haplotype; the nonoverlapping
95% conﬁdence intervals for the Odds Ratios between the
two DPB1*0101 haplotypes suggests a contributory role of
DPA1 (Table 2). These observations were conﬁrmed in the
HLA-B-DRB1-DQA1-DQB1 conditional analysis (Fig. 1)
and are the most widely reported and now replicated DP
associations with type 1 diabetes.
The low frequency DPB1*0202 allele was associated
with susceptibility following the DRB1-DQA1-DQB1 con-
ditional analysis (Padj  4  10
	3,O R 2.0) and in
haplotypic association with DPA1*0103 (Padj  7  10
	3,
OR  2.1). This association was conﬁrmed following the
HLA-B-DRB1-DQA1-DQB1 conditional analysis where the
expected frequency of DPA1*0103-DPB1*0202 was zero
whereas the observed frequency in type 1 diabetic patients
was 2.8% (data not shown).
Relative predispositional analysis. The distinct hierar-
chy of risk and protection established for individual DRB1-
DQA1-DQB1 haplotypes among the T1DGC families has
been reported (7). The role of HLA DP was therefore
considered both in the presence or absence of the
DRB1*0301-DQA1*0501-DQB1*0201, DRB1*0401-DQA1*
0301-DQB1*0302, DRB1*0402-DQA1*0301-DQB1*0302,
DRB1*0404-DQA1*0301-DQB1*0302, DRB1*0405-DQA1*
0301-DQB1*0302 high risk DR-DQ haplotypes and the
DRB1*0701-DQA1*0201-DQB1*0303, DRB1*1401-DQA1*
0101-DQB1*0503 and DRB1*1501-DQA1*0102-DQB1*0602
protective haplotypes (Table 3).
DPB1*0301 was signiﬁcantly associated with suscepti-
bility both in the presence or absence of the high risk and
protective DR-DQ haplotypes either individually or in
association with DPA1*0103 with an odds ratio of between
1.8 and 1.9. DPB1*0402, either individually or in associa-
tion with DPA1*0103, was observed to be signiﬁcantly
associated with protection only in the absence of the high
risk and protective DR-DQ haplotypes with an odds ratio
of 0.4.
The protective association of DPA1*0103-DPB1*0101
and susceptibility association of DPB1*0202 (DPA1*0103-
DPB1*0202) only observed in the high risk and protective
DR-DQ haplotypes is consistent with the presence of DR3
positive haplotypes in this group. The low frequency
susceptibility association with DPB1*1501 (or DPA1*0104-
DPB1*1501) observed in the absence of high risk and
protective DR-DQ haplotypes and in the conditional anal-
ysis (Table 2) may represent an additional secondary
association but requires conﬁrmation.
DPA1-DPB1 haplotype distribution in individual
DRB1-DQA1-DQB1 haplotypes. A comparison of the
DPA1-DPB1 odds ratios in the most frequent DRB1-DQA1-
DQB1 haplotypes suggests that DPA1*0103-DPB1*0301
and DPA1*0103-DPB1*0201 are associated with suscepti-
bility and DPA1*0103-DPB1*0402 with protection across
most DR-DQ haplotypes (Table 4). Only a single DPA1-
DPB1 association with either the combined or individual
DR4-DQB1*0302 positive haplotypes reached statistical
signiﬁcance; susceptibility associated with DRB1*0401-
DQA1*0301-DQB1*0302 was signiﬁcantly reduced by the
presence of DPA1*0103-DPB1*0101 (Padj  0.04, OR 
0.2). In contrast, the risk associated with DR3 (DRB1*
0301-DQA1*0501-DQB1*0201) positive haplotypes was sig-
niﬁcantly reduced by the presence of DPA1*0103-
DPB1*0402 (Padj  5  10
	3,O R 0.4) and the infrequent
DPA1*0103-DPB1*0101 (Padj  5  10
	6,O R 0.2) and
increased by the presence of DPA1*0103-DPB1*0202
(Padj  0.04, OR  2.5).
The effect of DP haplotypes on DR3 haplotypes was
further divided into three categories based on the pres-
ence of the extended haplotypes A1-B8-DR3 (A*0101-
B*0801-C*0701-DRB1*0301-DQA1*0501-DQB1*0201) and
A30-B18-DR3 (A*3002-B*1801-C*0501-DRB1*0301-DQA1*
0501-DQB1*0201) and “other” DR3 haplotypes. The sus-
ceptibility associated with the A1-B8-DR3 haplotype was
signiﬁcantly reduced by the presence of DPA1*0103-
DPB1*0402 (Padj  0.04, OR  0.4) and increased by the
presence of DPA1*0103-DPB1*0301 (Padj  0.03, OR  1.2)
and the low frequency DPA1*0103-DPB1*0202 (Padj  0.03,
OR  3.5). DPA1*0103-DPB1*0202 was associated with
susceptibility on the A30-B18-DR3 extended haplotype as
well as on “other” DR3 haplotypes but did not reach
statistical signiﬁcance in these haplotype comparisons.
The presence of DPA1*0103-DPB1*0101 (Padj  5 
10
	6,O R 0.1) but not DPA1*0201-DPB1*0101 signiﬁ-
cantly reduced the risk associated with “other” DR3 posi-
tive haplotypes with a nonoverlapping 95% CI (data not
shown) and nonsigniﬁcantly reduced the risk associated
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DR3 haplotype the only difference between those carrying
DPA1*0101-DPB1*0101 and DPA1*0201-DPB1*0101 is
likely to be the DPA1 allele or a gene in linkage
disequilibrium.
DISCUSSION
Previous association studies of HLA DP polymorphism
with type 1 diabetes using a variety of typing approaches
in different populations have indicated a susceptibility
association with DPB1*0301 and *0202 and a protective
association with DPB1*0402 as well as a number of
conﬂicting associations. In this publication, the Type 1
Diabetes Genetic Consortium provides a large scale asso-
ciation analysis of DPA1, DPB1 allele and DPA1-DPB1
haplotypes in a new type 1 diabetes Caucasian family
collection combined with existing collections that were
re-typed for HLA using the same platform. Seventy four
different DPA1-DPB1 haplotypes were observed; 19 DPB1
alleles were associated with multiple DPA1 alleles which
permits, for the ﬁrst time, a more precise type 1 diabetes
association analysis for DP and an assessment of the role
of DPA1.
A direct comparison of proband and AFBAC frequency
distributions showed that the frequency of one DPA1, four
DPB1 alleles and four DPA1-DPB1 haplotypes differed
signiﬁcantly when probands and AFBACs were compared;
the most signiﬁcant association was protection with
DPA1*0103-DPB1*0402.
HLA-DP association analyses in type 1 diabetes are
complicated by the extensive linkage disequilibrium
across the HLA region, in particular with the HLA-DR-DQ
region, which confers high risk for type 1 diabetes. In
order to adjust for these factors, analyses were performed
conditional on HLA-DRB1-DQA1-DQB1 and HLA-B-DRB1-
DQA1-DQB1 linkage disequilibrium and in the presence or
absence of the primary susceptibility and protective hap-
lotypes (relative predispositional analysis).
The conditional analyses conﬁrmed the previously de-
scribed HLA-DP associations, now reported as DPA1-
DPB1 haplotypes; susceptibility with DPB1*0301 (DPA1*
0103-DPB1*0301), DPB1*0202 (DPA1*0103-DPB1*0202)
and protection with DPB1*0402 (DPA1*0103-DPB1*0402).
A novel haplotype association observed here, reﬂecting
the potential role of DPA1, is the protective effect of
DPB1*0101 in association with DPA1*0103 but not when
linked to DPA1*0201. These alleles and haplotypes may
either encode secondary class II HLA molecules involved
in the presentation of a putative “diabetogenic peptide” or
are in linkage disequilibrium with another putative causal
gene.
The relative predispositional analysis, performed in the
presence or absence of the high risk susceptibility and
protective DR-DQ haplotypes, conﬁrmed the association
of susceptibility with DPA1*0103-DPB1*0301 across both
groups, whereas protection with DPA1*0103-DPB1*0402
only reached statistical signiﬁcance in the absence of the
high risk susceptibility and protective DR-DQ haplotypes.
The susceptibility association with DPA1*0103-DPB1*0202
and protective association with DPA1*0103-DPB1*0101
were observed only in the presence of the high risk
susceptibility and protective DR-DQ haplotypes. This is
consistent with the presence of DR3 positive haplotypes in
this group.
The contribution of DP to DR3 positive haplotypes was
further examined by comparing the risk associated with
the presence or absence of the extended A1-B8-DR3 and
A30-B18-DR3 haplotypes. The A1-B8-DR3 haplotype has
previously been shown to be associated with a lower risk
and the A30-B18-DR3 haplotype with a high risk to type 1
diabetes (35). The risk associated with the A1-B8-DR3
haplotype, which shows remarkable conservation of se-
quence between unrelated individuals (36), was signiﬁ-
cantly increased by the presence of DPA1*0103-
DPB1*0301 and DPA1*0103-DPB1*0202 and reduced by
the presence of DPA1*0103-DPB1*0402. DPB1 allele dif-
ferences therefore appear to stratify the susceptibility risk
on an otherwise conserved HLA haplotype. In contrast
only a single DP haplotypic association with DR4-
DQB1*0302 positive haplotypes was observed; the
DRB1*0401-DQA1*0301-DQB1*0302 haplotype was signif-
icantly reduced by the presence of DPA1*0103-DPB1*0101.
The DP haplotype *0103-*0202 is also increased among
patient A30-B18-DR3 haplotypes, but the difference does
not reach statistical signiﬁcance, perhaps due to a power
issue as DPA1*0103-DPB1*0202 has previously been asso-
ciated with increased susceptibility when not in associa-
tion with A30-B18-DR3 in Filipino type 1 diabetic patients
(37). The risk associated with the remaining DR3 positive
haplotypes was signiﬁcantly decreased by the presence of
DPA1*0103-DPB1*0101 but not by DPA1*0201-DPB1*0101
with nonoverlapping conﬁdence intervals. It is plausible
that HLA-DPA1 or another gene in linkage disequilibrium
may contribute to the signiﬁcant differences in associated
risk. DPA1 is the closest expressed gene centromeric to
HLA-DOA, which has recently been signiﬁcantly associ-
ated with type 1 diabetes risk in a study that initially
utilized the conservation of the A30-B18-DR3 haplotype to
examine other DR3 positive haplotypes (38).
A comparison of the amino acid sequences of
DPA1*0103 and DPA1*0201 shows they differ by two
substitutions at positions 31 (M versus Q) and 50 (Q versus
R); the latter substitution results in a charge difference
with a limited effect on peptide binding (39). However, the
same DPA1 allele difference in association with DPB1*
0301 has been observed to signiﬁcantly alter T cell recog-
nition (40) and monoclonal antibody recognition (41),
suggesting that these DPA1 differences do contribute to
functional and antigenic differences. Evidence for the
potential role of individual amino acids to type 1 diabetes
susceptibility is also highlighted by the protective associ-
ation of DPA1*0103-DPB1*0402 and the susceptibility
association of DPA1*0103-DPB1*0201. A comparison be-
tween the two haplotype sequences reveals a single K to E
difference at position 69 of DPB1. It is of note that a
second susceptibility association, DPA1*0103-DPB1*0202,
is also E positive at position 69, suggesting a critical role
for this residue. This substitution has previously been
implicated in inﬂuencing T cell recognition (12,42,43) and
changing peptide binding properties, resulting in an in-
crease in the afﬁnity of pocket four for positively charged
aromatic and polar residues (44). The corresponding po-
sition in the DR beta chain, amino acid residue 71, has
been shown to strongly inﬂuence peptide binding in auto-
immune related DRB1 alleles (45) and pocket four to be
important in determining susceptibility of DRB1*04 alleles
in type 1 diabetes (46).
The observations reported here conﬁrm and further
delineate the contributory role of DPA1 and DPB1 allelic
and haplotypic diversity with the risk associated to type 1
diabetes. Susceptibility is associated with DPB1*0301
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0202) and protection with DPB1*0402 (DPA1*0103-
DPB1*0402) and DPA1*0103-DPB1*0101 but not DPA1*
0201-DPB1*0101. The pattern of DP association on several
different DR-DQ haplotypes is consistent with the notion
that speciﬁc DPA1 and DPB1 alleles play a potential causal
role in type 1 diabetes susceptibility rather than as haplo-
type markers. Additional evidence is presented to suggest
that individual amino acid substitutions may inﬂuence
type 1 diabetes risk.
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